Mode
Text Size
Log in / Sign up
N/A N=117 Treatment

Effectiveness and Implementation of the HiBalance Program in Clinical Practice

Parkinson Disease

Enrolled (actual)
117
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Change in Mini-BESTest Score From Baseline at 1 Week Post Intervention. — 2.0; -0.2 score on a scale — p=< 0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
HiBalance training program (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Karolinska Institutet
Primary completion
Feb 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Mini-BESTest Score From Baseline at 1 Week Post Intervention.
2.0; -0.2 < 0.001 sig
SECONDARY
Change in 10-meter Walking Test Score From Baseline at 1 Week Post Intervention.
0.2; -0.04 =0.001 sig
SECONDARY
Change in Timed Up and Go (TUG) Test From Baseline at 1 Week Post Intervention.
-0.4; 0 0.254
SECONDARY
Change in EQ-5D Score From Baseline at 1week Post Intervention.
5.5; 0 =0.065
SECONDARY
Change in Activities-specific Balance Confidence (ABC) Scale
68; 70 =0.301
SECONDARY
Change in Physical Activity Level From Baseline 1 Week Post Intervention.
-288; -390 =0.792
SECONDARY
Change in Dual Task Interference During the Timed Up and Go (TUG) Test From Baseline at 1 Week Post Intervention.
-1.22; 1.05 0.039 sig

Summary

This effectiveness-implementation study is a part of the larger study BETA-PD (Balance, Elderly, Training and Activity in Parkinson's Disease), which has the long-term goal to reduce the risk of falling in people with Parkinson's disease (PD) by improving balance, gait and physical activity level. The main hypothesis is that highly challenging balance training will lead to greater gait and balance ability, increased levels of physical activity and an improved health related quality of life. The main aims of the study are to evaluate the effectiveness of the HiBalance program in real-life clinical settings, while exploring facilitators and barriers for program implementation on a wider scale.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed idiopathic Parkinson's Disease
  • Measured balance impairment (according to the mini-BESTest)
  • Hoehn and Yahr stages 2-3
  • Independent ambulator indoors without a walking aid

Exclusion Criteria

  • Cognitive impairment which hinders participation in group training
  • The presence of comorbidities which hinder safe participation in group training
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02727478). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search